Natalie Fragoso, MD
Dermatology · Lebanon, NHNPI 1922531201
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,522 of the $4,090 with a category attached, or 86.1%. UCB, Inc. accounts for 87.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $1,985 and has fallen 93.4% since, to $132 in 2025.
Across 11 payments — averaging $371.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$4K
- Johnson & Johnson$280
- Pfizer$134
- Novartis$93
- AbbVie$21
Across 5 payments — averaging $8384.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$42K
What the payments were for
- Consulting fees$3,52286%
- Food & beverage$40310%
- Education$1654%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 3 | $3,562 |
| Johnson & Johnson | 3 | $280 |
| Pfizer | 2 | $134 |
| Novartis | 2 | $93 |
| AbbVie | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,090 in reported general payments places this provider in the 65th percentile of 75 dermatology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 16 | $214,578 |
| Dupixent PenDupilumab | 38 | $132,116 |
| Tacrolimus | 33 | $4,256 |
| Fluorouracil | 68 | $4,221 |
| Clobetasol Propionate | 84 | $2,549 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 43 | $1,845 |
| Ketoconazole | 86 | $1,267 |
| Fluocinonide | 34 | $1,168 |
| Metronidazole | 23 | $1,139 |
| Clindamycin Phosphate | 34 | $1,114 |
| Triamcinolone Acetonide | 83 | $858 |
| Spironolactone | 34 | $752 |
| Doxycycline Monohydrate | 22 | $734 |
| Minoxidil | 49 | $696 |
| Desonide | 21 | $548 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Lebanon
- Yulianna RussakLebanon$170K
- Michael ChapmanLebanon$39K
- Denise AaronLebanon$8K
- Emily ShaughnessyLebanon$6K
- Nicole PaceLebanon$6K
- Brian SimmonsLebanon$3K
- Elizabeth MarvinLebanon$1K
- Joi CarterLebanon$135
- Chenin RyanLebanon$87
- Alicia DagrosaLebanon$65
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.